Although promoted as an alternative
therapy for depression, the herbal supplement St. John's wort appears
ineffective for people with moderate clinical depression.
In the study of 340 patients
diagnosed with moderate depression, St. John's wort proved no more effective
than inactive treatment with a placebo in alleviating symptoms. Active
treatment with the antidepressant drug Zoloft worked somewhat better than
placebo.
A body of evidence suggests
that St. John's wort (Hypericum perforatum), used for more than 2,000
years to quell mood problems, does help symptoms of depression. In Germany,
where many of the positive studies have been conducted, St. John's wort
is available as a prescription antidepressant.
But
the quality of much of this research has been criticized
-- including the lack of studies using
a placebo and a selective serotonin reuptake inhibitor (SSRI)
like Zoloft according to the authors of the new study. SSRIs are a newer
class of drugs commonly used to treat depression.
To address these concerns about
earlier studies, researchers assigned patients to take St. John's wort,
sertraline or placebo for up to 26 weeks.
At the study's end, the researchers
found that neither the herb nor the
drug was better than placebo in improving patients' scores
on a standard scale of depressive symptoms. Overall, nearly one third
of placebo patients showed a full response to treatment, compared with
roughly 24% in both the St. John's wort and Zoloft groups.
Patients on Zoloft did, however,
do better than placebo patients on a secondary test used to gauge a person's
daily functioning and levels of distress. The Zoloft group also had a
higher percentage of so-called "partial responders" to treatment
than either the placebo or St. John's wort groups.
Still, the findings do not
indicate whether the herb can help people with mild depressive symptoms
-- a question additional research will have to address. St. John's wort
is marketed for the treatment of mild to moderate depression, but it's
likely people with a range of depressive disorders try the herb.
The researchers believed that
dosing almost certainly contributed to Zoloft's less-than-stellar performance
in the study.
This study -- along with a
second one in the same journal issue documenting the rise
of the "placebo effect" in recent research on depression drugs
-- highlight the importance of using a placebo and an active
comparison drug in studies of unproven antidepressant agents.
The main researcher for the
study holds stock in Pfizer, the maker of Zoloft, and has received speaker
fees from Pfizer. Co-authors on the study have received funding from a
number of pharmaceutical companies. The study itself was funded by the
US National Institutes of Health.
JAMA
April 10, 2002;287:1807-1814, 1853-1854
|